Shares of Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) were up 13% on Monday . The company traded as high as $0.53 and last traded at $0.52. Approximately 963,509 shares changed hands during trading, a decline of 33% from the average daily volume of 1,444,606 shares. The stock had previously closed at $0.46.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last posted its quarterly earnings data on Tuesday, August 14th. The specialty pharmaceutical company reported $0.05 EPS for the quarter.
A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers acquired a new stake in shares of Ampio Pharmaceuticals during the 2nd quarter valued at $154,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Ampio Pharmaceuticals during the 2nd quarter valued at $326,000. Bank of New York Mellon Corp boosted its stake in shares of Ampio Pharmaceuticals by 290.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 202,590 shares of the specialty pharmaceutical company’s stock valued at $446,000 after buying an additional 150,664 shares during the period. Courier Capital LLC boosted its stake in shares of Ampio Pharmaceuticals by 2,032.7% during the 3rd quarter. Courier Capital LLC now owns 304,973 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 290,673 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new stake in shares of Ampio Pharmaceuticals during the 2nd quarter valued at $155,000.
ILLEGAL ACTIVITY NOTICE: “Ampio Pharmaceuticals (AMPE) Trading Up 13%” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/07/ampio-pharmaceuticals-ampe-trading-up-13.html.
About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Further Reading: What is a stock split?
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.